Amplyx Pharmaceuticals Secures $40,500,000 Series B Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1720ac29-477f-4544-bfbf-b51b61b128e7
Date
11/11/2015
Company Name
Amplyx Pharmaceuticals
Mailing Address
3210 Merryfield Row San Diego, CA 92121 USA
Company Description
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
Website
http://www.amplyx.com
Transaction Type
Venture Equity
Transaction Amount
$40,500,000
Transaction Round
Series B
Proceeds Purposes
Amplyx will use the funding to advance the clinical development of APX001, the company’s broad-spectrum antifungal agent to treat life threatening fungal infections.
M&A Terms
Venture Investor
RiverVest Venture Partners
Venture Investor
New Enterprise Associates
Venture Investor
BioMed Ventures